Alumni des start-ups

Depuis la première spin-off créée en 1997, de nombreuses entreprises ont démarré leur activité à l’Institut Pasteur et continuent généralement d’entretenir des relations avec lui.

Testimony

Eligo Bioscience is a next-generation microbiome precision medicine company. Eligo Bioscience is pioneering the development of phage-derived DNA delivery vectors for microbial species involved in a number of disease areas, including infectious diseases, inflammatory diseases and auto-immune diseases.

Eligo Bioscience was set up in 2014 based on research from the Lu Lab (MIT, USA) and the Marraffini Lab (Rockefeller University, USA). Eligo was incubated at the Institut Pasteur in Paris from 2014 to 2017 and moved to the “Paris Biotech Santé” biotech cluster at Cochin Hospital in 2017.

David Bikard, Co-founder and CSO of Eligo Bioscience, is Head of the Synthetic Biology Lab at the Institut Pasteur.

 

 

David Bikard, Co-founder and CSO of Eligo Bioscience, is Head of the Synthetic Biology Lab at the Institut Pasteur.

 

Xavier Duportet, Co-founder and CEO of Eligo Bioscience

Our continued collaboration with the Institut Pasteur creates a continuous link between basic research and real-life applications, while providing access to important biological resources and cutting edge-technologies. This fluid interaction is critical to our progress.